Coherus Oncology (CHRS) Gross Profit (2019 - 2025)
Historic Gross Profit for Coherus Oncology (CHRS) over the last 7 years, with Q3 2025 value amounting to $7.8 million.
- Coherus Oncology's Gross Profit rose 13623.23% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $156.4 million, marking a year-over-year increase of 69640.97%. This contributed to the annual value of $149.4 million for FY2024, which is 5206.51% up from last year.
- According to the latest figures from Q3 2025, Coherus Oncology's Gross Profit is $7.8 million, which was up 13623.23% from $6.9 million recorded in Q2 2025.
- Over the past 5 years, Coherus Oncology's Gross Profit peaked at $136.7 million during Q4 2024, and registered a low of $869000.0 during Q1 2024.
- Moreover, its 5-year median value for Gross Profit was $31.2 million (2022), whereas its average is $35.6 million.
- Data for Coherus Oncology's Gross Profit shows a peak YoY increase of 186532.99% (in 2024) and a maximum YoY decrease of 9441.59% (in 2024) over the last 5 years.
- Over the past 5 years, Coherus Oncology's Gross Profit (Quarter) stood at $61.2 million in 2021, then plummeted by 49.14% to $31.2 million in 2022, then plummeted by 77.67% to $7.0 million in 2023, then skyrocketed by 1865.33% to $136.7 million in 2024, then tumbled by 94.26% to $7.8 million in 2025.
- Its Gross Profit was $7.8 million in Q3 2025, compared to $6.9 million in Q2 2025 and $4.9 million in Q1 2025.